Featured Research

Patients and doctors are being misled by published data on medicines, Germany study suggests

Date:

October 12, 2010

Source:

BMJ-British Medical Journal

Summary:

The drug reboxetine is, overall, an ineffective and potentially harmful antidepressant, according to a comprehensive study of the evidence by a team of researchers in Germany. The study also shows that nearly three quarters of the data on patients who took part in trials of reboxetine were not published until now, and that the published data on the drug overestimate the benefits and underestimate the harms of treatment -- all underlining the urgent need for mandatory publication of all clinical trial results.

Related Articles

The study also shows that nearly three quarters of the data on patients who took part in trials of reboxetine were not published until now, and that the published data on the drug overestimate the benefits and underestimate the harms of treatment -- all underlining the urgent need for mandatory publication of all clinical trial results.

Reboxetine has been approved for the treatment of major depressive disorder in many European countries since 1997, but doubts have been raised about its effectiveness on the basis of recent studies and rejection of the application for approval in the United States in 2001. Published trials, however, show a favourable risk-benefit profile for reboxetine.

So a team of researchers at The German Institute for Quality and Efficiency in Health Care (IQWiG) set out to assess the benefits and harms of reboxetine compared with placebo or other antidepressants, known as selective serotonin reuptake inhibitors (SSRIs), for treating adults with major depression.

They also measured the impact of potential publication bias in trials of reboxetine (where positive trial results are more likely to be published than unfavourable results).

They analysed the results of 13 trials, including eight previously unpublished trials from the manufacturer of reboxetine (Pfizer). The overall quality of the trials was good, but the researchers noted that data on 74% of patients were unpublished.

They show that reboxetine is, overall, an ineffective and potentially harmful antidepressant. They found no significant difference in benefit (remission and response rates) versus placebo and inferior benefit versus SSRIs, as well as a higher rate of patients affected by adverse events than with placebo and higher withdrawal rates owing to adverse events than with placebo and the SSRI fluoxetine.

A further comparison of published and unpublished trials shows that published data overestimated the benefit of reboxetine and underestimated harm.

This, say the authors, is a striking example of publication bias, resulting in a distorted public record of a treatment. Publication bias can affect health policy decisions and the content of clinical guidelines, they warn. "Our findings underline the urgent need for mandatory publication of trial data."

In an accompanying analysis, the same authors argue that current regulations on the publication of trial results are insufficient. They believe several measures are required in order to provide patients, clinicians, and health policy makers with unbiased and verified evidence on which to base decisions.

These include mandatory public disclosure of data for all drugs, even for those never approved, public access to trials of older drugs not covered by current law, greater data sharing between regulatory authorities, as well as re-evaluation of a drug if approval is declined elsewhere, and a legal obligation for manufacturers to provide all requested data to official bodies without restrictions to publication.

In a second analysis, senior researchers Robert Steinbrook and Jerome Kassirer highlight several recent examples that illustrate the problems of trusting drug companies to provide the complete picture about the clinical trials they sponsor. They propose that journals should define full access to all the trial data and require that investigators and journal editors have full access. Editors should also take appropriate action if concerns about data arise after publication. "Trust in the medical literature, not just in industry sponsored trials, is at stake," they conclude.

In an accompanying editorial, BMJ Editors Dr Fiona Godlee and Dr Elizabeth Loder, argue that "the medical evidence base is distorted by missing clinical trial data" and that "urgent action is needed to restore trust in existing evidence."

They believe it is important to re-evaluate the integrity of the existing base of research evidence and, as such, the BMJ will devote a special theme issue to this topic in late 2011.

"Full information about previously conducted clinical trials involving drugs, devices and other treatments is vital to clinical decision-making," they say. "It is time to demonstrate a shared commitment to set the record straight."

BMJ-British Medical Journal. "Patients and doctors are being misled by published data on medicines, Germany study suggests." ScienceDaily. ScienceDaily, 12 October 2010. <www.sciencedaily.com/releases/2010/10/101012192129.htm>.

BMJ-British Medical Journal. (2010, October 12). Patients and doctors are being misled by published data on medicines, Germany study suggests. ScienceDaily. Retrieved March 31, 2015 from www.sciencedaily.com/releases/2010/10/101012192129.htm

BMJ-British Medical Journal. "Patients and doctors are being misled by published data on medicines, Germany study suggests." ScienceDaily. www.sciencedaily.com/releases/2010/10/101012192129.htm (accessed March 31, 2015).

More From ScienceDaily

More Science & Society News

Featured Research

Mar. 31, 2015  Fewer than half of the physicians trained in the United States in 2013 received formal education or training on the subject of exercise, according to new research. "There are immense medical benefits ... full story

Mar. 31, 2015  A criminologist finds that solitary confinement does not deter inmates from committing further violence in prison. The prisoners in the study who received solitary confinement were no more -- or less ... full story

Mar. 31, 2015  Increasing state alcohol taxes could prevent thousands of deaths a year from car crashes, say researchers, who found alcohol-related motor vehicle crashes decreased after taxes on beer, wine and ... full story

Mar. 31, 2015  Human language likely developed quite rapidly into a sophisticated system, a linguist contends. Instead of mumbles and grunts, people deployed syntax and structures resembling the ones we use today, ... full story

Mar. 31, 2015  New research reveals high-quality early education is especially advantageous for children when they start younger and continue longer. Not only does more high-quality early education significantly ... full story

Mar. 31, 2015  Differences in the way children and adults perceive the world extend to their sense of safety in their social and physical environments and this in turn can impact their health, say researchers. ... full story

Mar. 31, 2015  Researchers have detected a human fingerprint deep in the Borneo rainforest in Southeast Asia. Cold winds blowing from the north carry industrial pollutants from East Asia to the equator, with ... full story

Mar. 31, 2015  Landfills can make a profit from all their rotting waste and a new patent explains exactly how to make the most out of the stinky garbage sites. Decomposing trash produces methane, a landfill gas ... full story

Mar. 31, 2015  As the United States faces transplant waiting lists that continue to grow longer over time, there is increasing debate about the proper way to incentivize living donations. Due to organ shortages, ... full story

Mar. 30, 2015  The moon does not influence the timing of human births or hospital admissions, a new study finds, confirming what astronomers have known for decades. The study illustrates how intelligent people ... full story

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015)  Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline.
Video provided by Washington Post

Related Stories

Mar. 17, 2015  Advice to use the anti-clotting drug alteplase more than three hours after an acute stroke should be re-evaluated, say researchers. Most major stroke guidelines support use of alteplase up to 4.5 ... full story

Mar. 16, 2015  A review of clinical trial data suggests vitamin D supplementation was ineffective at lowering blood pressure and should not be used as an antihypertensive, according to an ... full story

Oct. 22, 2013  Having a different form of a gene that regulates the brain chemical noradrenaline influences how well men remember negative memories after taking the antidepressant drug reboxetine, according to a ... full story

Oct. 5, 2011  An international non-profit organization committed to providing the most reliable evidence of the benefits and harms of healthcare interventions has released a statement calling for free access to ... full story

May 25, 2010  Researchers have compiled over 60 examples illustrating how the dissemination of medical knowledge has been impeded. For this purpose, they assessed hundreds of citations. A wide range of ... full story

ScienceDaily features breaking news and videos about the latest discoveries in health, technology, the environment, and more -- from major news services and leading universities, scientific journals, and research organizations.